In summary, our study demonstrated that VSTM2A sterically blocks PD-1 binding to PD-L1 at a picomole to nanomole affinity, which leads to the enhanced anti-tumor effect of cytotoxic T cells. The gene discussed is PDCD1; the disease is neoplasm.